Cardiac Risk Stratification | Core Laboratory at Abbott

High Sensitive Troponin-I can help to more accurately identify elevated risk of a future cardiac event, even in apparently healthy individuals.

Abbott's High Sensitive Troponin-I (hsTnI) blood test can help to identify patients who are at high-risk or potentially at high-risk of heart attacks, heart failure or cardiovascular disease, including cardiovascular death, MI, coronary revascularization, heart failure, or ischemic stroke. The result, in conjunction with clinical and diagnostic findings, can then be used to prioritize the care of at-risk patients and develop a treatment plan that mitigates the risk of unfavorable outcomes.^2,3

Troponin I is specific to the heart and therefore it can more accurately categorize patients' risk, in conjunction with other clinical and diagnostic findings, before they experience a cardiovascular event.^1–3

There are a variety of cardiovascular (CV) risk prediction models currently available, however no other test is specific to the heart. These other models, which take into consideration the presence of CV risk factors, are indirect methods that pose challenges due to their:

focus on age and ethnicity
applicability only in certain populations
ability to measure a limited number of CV outcomes.^4,5

→ Hear directly from customers who have been using the test in the day-to-day practice.

High sensitive troponin-I – Early cardiac risk stratification model

Abbott's hsTnI can detect troponin, which is released when heart muscle is injured, even at low levels. Using the results from an hsTnI blood test can help you to more accurately stratify the risk of a future cardiac event in an asymptomatic individual into one of three categories:^2,3

In conjunction with clinical and diagnostic findings, it enables you to better prioritize appropriate care for those at higher risk to help prevent adverse outcomes, and potentially avoid unnecessary investigations and treatments in those at lower risk.

Through this early cardiac risk identification model, long-term lifestyle changes and targeted treatments can be recommended to patients before a cardiac incident takes place.⁷ This helps you to empower patients to take control of their well-being by making healthy choices.

WHAT DO ABBOTT'S HSTNI
RESULTS MEAN?

Abbott's hsTnI results, are to be applied to the
risk stratification table shown below:

Identify

Identify risk based on the addition of a cardiac specific test showing the presence of cardiac muscle injury. Assess which risk category (low/moderate/elevated) an individual falls into based on the corresponding troponin I level. An accompanying statement interpreting these results, may be provided.

Predict

Clinically assess the information provided by hsTnI in addition to classic risk factors and guideline-driven management of risk. Use your clinical judgement and adhere to recommended cardiovascular prevention guidelines to determine the standard of care appropriate for your patient based upon their level of risk.

Act

Utilize the new heart-specific variable to motivate your patients to take action to make healthier living choices to improve their heart health.

The following cut-off points may be used to aid in stratifying the risk of cardiovascular disease in asymptomatic individuals:^2,3,6

Cardiac-specific risk assessment that more accurately predicts future cv events

The power of sensitivity

Learn from distinguished physicians how troponin is helping in the accurate identification of patients’ cardiac risk.

Role of troponin-I in identifying risk of a future cardiac event

Watch how assessing troponin I levels in the apparently healthy population can help identify a patient with an elevated risk of a future cardiac event with more accuracy.

Troponin as the direct signal coming from the heart

Learn the differences between traditional cardiac risk factors and troponin.

Abbott's hstni cardiac risk stratification versus other current tools

Current risk-stratification tools such as Framingham, SCORE, and Lipid profile are not cardiac-specific and can be overly influenced by age. Abbott's hsTnI risk stratification blood test contains the protein troponin I, which is specific to the heart. This means it can more accurately categorize patients' risk when used in conjunction with clinical and diagnostic findings.^6,8–11

Early detection to more accurately evaluate risk of future cardiac events, in conjunction with other clinical and diagnostic findings.⁶

Greater accuracy in identifying lower-risk patients, which may avoid unnecessary testing, treatments, and potential side effects.⁶

Potential to reduce the growing cost burden to the healthcare system by appropriately recategorizing at-risk patients.⁶

Abbott's hsTnI is not impacted by biotin interference.¹²

Find out more about how hsTnI can more accurately predict the risk of a future
cardiac event even in an apparently healthy population.

Download physician resource

Troponin customer experience

Troponin – A mirror of cardiac health?

Cardiologists Professor Dr. Christoph Liebetrau and Associate Professor Dr. Till Keller from the Cardiac Center in Bad Nauheim, Germany discuss the significance of cardiac risk stratification with troponin I and possible areas of application.

Resources

Physician Pathway

Risk Stratification Opinion Piece

Measurably Better Health Care Performance - Troponin Risk Stratification

Physician Resource

Identify. Predict. Act

Add Abbotts High Sensitive Troponin-I cardiac specific blood test to your patients' health check. And help change lives.

Request more info

Explore

Understand the Value of Troponin

Explore how High Sensitive Troponin may enable easier management of patients with suspect AMI.

Learn more about troponin

Cardiac Assays

Instill confidence in your cardiac care decision making with our comprehensive cardiac assay menu.

View cardiac solutions

Visit the Knowledge Center

Find the latest information in laboratory science, therapeutic areas and Abbott innovation.

Visit the knowledge center

References

Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020–35. doi.org/10.1161/CIR.0b013e31826e1058.
ARCHITECT STAT High Sensitive Troponin-I [package insert]. Lake Bluff, IL: Abbott Laboratories; 2018. G97079R01.
Alinity i STAT Troponin-I [package insert]. Lake Bluff, IL: Abbott Laboratories; 2019. H05938R01.
DeFilippis AP, Young R, Carrubba CJ et al. Ann Intern Med. 2015 Feb 17;162(4):266–75.
Garg N, Muduli SK, Kapoor A, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J. 2017;69(4):458–63. doi:10.1016/j.ihj.2017.01.015.
Sigurdardottir FD, Lyngbakken MN, Holmen OL, et al. Relative prognostic value of cardiac troponin I and C-reactive protein in the general population (from the Nord-Trøndelag Health [HUNT] Study). Am J Cardiol. 2018;121(8):949–55. doi.org/10.1016/j.amjcard.2018.01.004.
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.

Ford I, Shah ASV, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol. 2016;68(25):2719–28. doi:10.1016/j.jacc.2016.10.020.
Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J. 2016;37(30):24–37. doi:10.1093/eurheartj/ehw172.
Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S. High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015;131(21):18–60. doi:10.1161/CIRCULATIONAHA.114.014522.
Omland T, Lemos de, JA, Holmen OL et al. Impact of Sex on the Prognostic Value of High-Sensitivity Cardiac Troponin I in the General Population: The HUNT Study, Clin Chem. 2015 Apr;61(4):646–56.
Trambas C, Lu Z, Yen T et al. Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin–biotin immunoassays. Ann Clin Biochem. 2017;55(2):216–26.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

All ARCHITECT analyzers, Alinity hq, CELL-DYN Ruby, CELL-DYN Sapphire and CELL-DYN Emerald 22 AL instruments are Class I laser products. ACCELERATOR APS and ACCELERATOR a3600 are Class II laser products.

The Alinity, ARCHITECT, ACCELERATOR and CELL-DYN systems are intended for performing in vitro diagnostic assays on samples of human origin (blood, urine). Read the instructions in the system manuals and labeling and/or reagent instructions carefully. Manufacturer or Authorized Representative: Abbott Germany.

This website contains general information about our products sold worldwide. Product availability varies by country. For product availability in your country, please contact your local Abbott representative. Certain products described or certain features of some products described on this global page might not be commercially available in your country. Content is intended for healthcare professionals only.

ACCELERATOR

ALINITY

ALINIQ

ARCHITECT

CELL-DYN

GLP SYSTEMS TRACK

AUTOMATION

CLINICAL CHEMISTRY

END TO END SOLUTIONS

HEMATOLOGY

IMMUNOASSAY

More accurately identify Your patients' risk of A future cardiac event